Clinical Trial Update: Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluated the efficacy and safety of subcutaneous methylnaltrexone (MOA-728) for opioid-induced constipation; results have been posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Constipation

Drugs mentioned

• MOA-728 (methylnaltrexone) (methylnaltrexone)

Snippet

Sponsor: Bausch Health Americas, Inc. | Conditions: Constipation | Phase 3 | Status: COMPLETED | Results posted: 2020-01-02